Eli Lilly and Co Update on SARS-CoV-2 Neutralizing Antibody Program - Conference Call Summary - Thomson StreetEvents

Eli Lilly and Co Update on SARS-CoV-2 Neutralizing Antibody Program - Conference Call Summary

Eli Lilly and Co Update on SARS-CoV-2 Neutralizing Antibody Program - Conference Call Summary - Thomson StreetEvents
Eli Lilly and Co Update on SARS-CoV-2 Neutralizing Antibody Program - Conference Call Summary
Published Jan 26, 2021
19 pages (11408 words) — Published Jan 26, 2021
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Brief of LLY.N conference call or presentation 26-Jan-21 5:00pm GMT

  
Brief Excerpt:

...A. Details: Exciting last few months. 1. String of high quality pipeline readouts which increased confidence in long-term outlook. a. b. In near-term in US and around the globe, Co. remains focused on navigating the challenges of COVID-19 pandemic. 2. Co. remains committed to bring the full force of scientific and medical expertise to bear on the virus and to benefit the global community. Co. has multiple positive readouts in BLAZE clinical program, reinforcing the potential effectiveness of neutralizing antibodies in combating COVID-19. a. b. Start of efforts in March to the impressive progress in ensuing months, including exciting news in past several days. Contributing partners include partners that AbCellera and Junshi, the National Institute of Allergy and Infectious Disease in NIH, FDA and other global regulatory bodies, and investigators who helped Co. develop the data for the SARS-CoV-2 neutralizing antibody program, and patients who enrolled in BLAZE clinical program. i. c. Encouraged...

  
Report Type:

Brief

Source:
Thomson StreetEvents
Company:
Eli Lilly and Co
Ticker
LLY.N
Time
5:00pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Gregory B. Gilbert - Truist Securities, Inc., Research Division - Analyst : Thank you, team. Sorry if I missed this, but when would you be in a position where supply would not be an issue? I think you've commented on 2021 specifically, but at what point would supply not be an issue sort of regardless on the existing antibodies. And my second question is about vaccination. Some consumer research we've done very recently suggest that a pretty large portion of the U.S. population is not ready to get vaccinated, even if there is supply. Whether that's true or not or changes or not, how do vaccination rates shape your thinking about how these antibodies will be taken up and used and maybe as importantly, how you should study antibodies in a vaccinated world in the future?

Table Of Contents

Eli Lilly and Co at SVB Leerink Global Healthcare Conference (Virtual) Transcript – 2021-02-24 – US$ 54.00 – Edited Transcript of LLY.N presentation 24-Feb-21 6:40pm GMT

Eli Lilly and Co at Guggenheim Partners Healthcare Talks Oncology Days Transcript – 2021-02-12 – US$ 54.00 – Edited Transcript of LLY.N presentation 12-Feb-21 4:00pm GMT

Eli Lilly and Co Q4 2020 Earnings Call Summary – 2021-01-29 – US$ 54.00 – Edited Brief of LLY.N earnings conference call or presentation 29-Jan-21 2:00pm GMT

Eli Lilly and Co Q4 2020 Earnings Call Transcript – 2021-01-29 – US$ 54.00 – Edited Transcript of LLY.N earnings conference call or presentation 29-Jan-21 2:00pm GMT

Eli Lilly and Co Update on SARS-CoV-2 Neutralizing Antibody Program - Conference Call Transcript – 2021-01-26 – US$ 54.00 – Edited Transcript of LLY.N conference call or presentation 26-Jan-21 5:00pm GMT

Eli Lilly and Co at JPMorgan Healthcare Conference (Virtual) Transcript – 2021-01-12 – US$ 54.00 – Edited Transcript of LLY.N presentation 12-Jan-21 1:20pm GMT

Eli Lilly and Co 2021 Guidance Call Summary – 2020-12-15 – US$ 54.00 – Edited Brief of LLY.N guidance conference call or presentation 15-Dec-20 1:30pm GMT

Eli Lilly and Co 2021 Guidance Call Transcript – 2020-12-15 – US$ 54.00 – Edited Transcript of LLY.N guidance conference call or presentation 15-Dec-20 1:30pm GMT

Eli Lilly and Co at Evercore ISI HealthCONx Conference (Virtual) Transcript – 2020-12-01 – US$ 54.00 – Edited Transcript of LLY.N presentation 1-Dec-20 7:40pm GMT

Eli Lilly and Co to Provide an Overview of Tirzepatide Phase 3 Clinical Program - Conference Call Summary – 2020-11-20 – US$ 54.00 – Edited Brief of LLY.N conference call or presentation 20-Nov-20 4:00pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Eli Lilly and Co Update on SARS-CoV-2 Neutralizing Antibody Program - Conference Call Summary" Jan 26, 2021. Alacra Store. May 15, 2025. <http://www.alacrastore.com/thomson-streetevents-transcripts/Eli-Lilly-and-Co-Update-on-SARS-CoV-2-Neutralizing-Antibody-Program-Conference-Call-B13605109>
  
APA:
Thomson StreetEvents. (2021). Eli Lilly and Co Update on SARS-CoV-2 Neutralizing Antibody Program - Conference Call Summary Jan 26, 2021. New York, NY: Alacra Store. Retrieved May 15, 2025 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Eli-Lilly-and-Co-Update-on-SARS-CoV-2-Neutralizing-Antibody-Program-Conference-Call-B13605109>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.